IL37 and type 2 diabetes mellitus: In a recently published study including 480 hospitalized patients (aged 65–95 years) with newly diagnosed T2DM and 180 healthy subjects without glucose metabolism abnormalities, IL-37 was observed to have a protective role in the elderly T2DM patients and sensitized them to insulin therapy through suppressing the gut microbiota dysbiosis.